Category Archives: 2014

Taxotere is More Effective if Used Before Hormone Resistance Develops.

Taxotere (docetaxel®) and taxol are plant alkaloids derived from  the European yew tree, Taxus Baccata.  Taxotere is synthetically obtained by chemically converting a precursor extracted from the needles of the yew plant.  Administered intravenously, both are used to treat several more »

Posted in 2014 | 1 Comment

Xtandi (Enzalutamide) Now Approved for Metastatic, Hormone-Refractory Prostate Cancer Before Chemotherapy.

The following is an important blog in three sections. It describes another approved therapeutic agent for men with metastatic, hormone-refractory prostate cancer. Also included are important discussions regarding the need for future clinical studies to maximize cancer remissions and overall more »

Posted in 2014 | Leave a comment

A Phase III Trial Involving Enzalutamide in Men with Metastatic, Hormone-Resistant Prostate Cancer.

The Alliance for Clinical Trials in Oncology is conducting a Phase III clinical trial of enzalutamide (Xtandi®) with or without abiraterone acetate (Zytiga®) and prednisone in men with hormone-refractory, metastatic prostate cancer with the hope of improving overall survival.  Details more »

Posted in 2014 | 1 Comment

Affinity: A Phase III Trial Using Custirsen and Jevtana® for Men with Metastatic Hormone-Resistant Prostate Cancer.

The goal of the Phase III Affinity Trial is to test whether adding an experimental drug called custirsen to Jevtana® (cabazitaxel) chemotherapy can help treat men with hormone-resistant prostate cancer. In the latter case, chemotherapy with taxotere (docetaxel®) or  Jevtana® more »

Posted in 2014 | Leave a comment

Metformin Aids in the Stabilization of Metastatic Prostate Cancer

An article published in the January 4th, 2014 issue of the journal European Urology reported the outcome of a Swiss trial involving men with hormone-resistant (refractory) prostate cancer (defined as a testosterone level of less than 50 ng/dL with progressive more »

Posted in 2014 | Leave a comment

PROSPECT: A Phase III Clinical Trial of the Immunotherapy Vaccine Prostvac in Asymptomatic Hormone-Resistant Prostate Cancer Patients.

The goal of the Prospect Trial is to enhance a man’s immune system to fight prostate cancer. It is a Phase III trial for metastatic, hormone-resistant prostate cancer patients who are either asymptomatic or minimally symptomatic. The trial utilizes the more »

Posted in 2014 | Leave a comment

Encouragement from a Friend Experiencing Testing

As the purveyor of this website, I occasionally hear from other men who relate their experiences with prostate cancer. I’d like to recount the testimonial of one such person whom I know well. He has asymptomatic but metastatic prostate cancer more »

Posted in 2014 | Leave a comment

High-Grade Prostate Cancer Associated with Chronic Inflammation

In an online April 18th, 2014 publication in the journal Cancer Epidemiology, Biomarkers and Prevention, Johns Hopkins researchers reveal a link between chronic inflammation and a greater risk of high-grade prostate cancer. The study included 191 men with prostate cancer more »

Posted in 2014 | Leave a comment

Possible Link Between Low Vitamin D Levels and Prostate Cancer Risk

A recent study published in Clinical Cancer Research, (May 1, 2014; 20; 2289-99) indicated that men at risk of prostate cancer are more likely to develop an aggressive form of the disease if they are deficient in vitamin D. University more »

Posted in 2014 | Leave a comment

Two Blood Tests That Can Help Determine the Need for a Biopsy.

The latest edition of the Johns Hopkins Health Alerts (July 9th) cites two blood tests that can provide important information which, when coupled with a physician’s clinical judgment, can more accurately predict the need for a biopsy to confirm or more »

Posted in 2014 | Leave a comment